Skip to main content
Navigate Up
Sign In

Welcome to the Department of Neurology

Neurology Banner Image
 

MS/Neuroimmunology

Clinical Research



If you think you may qualify for one of these studies, please contact Professional Research Assistant (PRA) below for more information.

Search for: view all

COMIRB # Title (Please click on the title to see approved advertisement) Principal Investigator PRA
15-0293 A Double-Blind, Placebo-Controlled, Single Ascending Dose Intravenous Infusion Study of rHIgM22 in Subjects with Multiple Sclerosis Immediately Following a Relapse Alvarez, Enrique, MD Nicola Haakonsen
303-724-4644
Eligibility and Information
12-0968 Rocky Mountain Multiple Sclerosis Center (RMMSC) Biorepository for the Study of Neuroimmunological Disorders Alvarez, Enrique, MD Nicola Haakonsen
303-724-4644
Please contact PRA for eligibility and information
15-1194 A Phase II, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Multi-Dose Intravitreal Injections to Subjects With Acute Non Arteritic Anterior Ischemic Optic Neuropathy (NAION) Bennett, Jeffrey L., MD, PhD Nicola Haakonsen
303-724-4644
Eligibility and Information
16-0120 AN OPEN-LABEL, MULTICENTER, BIOMARKER STUDY TO EXPLORE THE MECHANISM OF ACTION OF OCRELIZUMAB AND B-CELL BIOLOGY IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS Bennett, Jeffrey L., MD, PhD Nicola Haakonsen
303-724-4644
Eligibility and Information
14-0598 A Multicenter, Randomized, Addition to Baseline Treatment, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SA237 in Patients With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD) Bennett, Jeffrey L., MD, PhD Nicola Haakonsen
303-724-4644
Eligibility and Information
13-0388 A Phase IV Trial of Neuroprotection with ACTH in Acute Optic Neuritis Bennett, Jeffrey L., MD, PhD Nicola Haakonsen
303-724-4644
Eligibility and Information
14-0926 A Phase 2/3, Double-masked, Placebo-controlled Study with Open-Label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Bennett, Jeffrey L., MD, PhD Nicola Haakonsen
303-724-4644
Eligibility and Information
13-3181 Collaborative International Research in Clinical and Longitudinal Experience for Neuromyelitis Optica (NMO) Studies (CIRCLES) Bennett, Jeffrey L., MD, PhD Nicola Haakonsen
303-724-4644
Please contact PRA for eligibility and information
08-0613 The role of TH40 cell in Multiple Sclerosis and Type 1 Diabetes Corboy, John R., MD Nicola Haakonsen
303-724-4644
Please contact PRA for eligibility and information
09-0952 Rocky Mountain MS Center Tissue Bank Corboy, John R., MD Nicola Haakonsen
303-724-4644
Please contact PRA for eligibility and information
16-0121 Multi-center, randomized, double-blinded assessment of Tecfidera® in extending the time to a first attack in radiologically isolated syndrome (RIS) (ARISE) Schreiner, Teri L., MD, MPH Nicola Haakonsen
303-724-4644
Eligibility and Information
16-0156 Natalizumab for Prevention of Post-Partum Relapses in Patients with Multiple Sclerosis Schreiner, Teri L., MD, MPH Nicola Haakonsen
303-724-4644
Eligibility and Information
13-2897 Cross-Sectional Study of MSDx Complex-1 Association with Gadolinium Enhancing Lesions in Relapsing-Remitting Multiple Sclerosis Schreiner, Teri L., MD, MPH Nicola Haakonsen
303-724-4644
Eligibility and Information
14-0388 Medication Adherence in Pediatric Multiple Sclerosis Schreiner, Teri L., MD, MPH Nicola Haakonsen
303-724-4644
Please contact PRA for eligibility and information
13-2897 A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM) Schreiner, Teri L., MD, MPH Nicola Haakonsen
303-724-4644
Eligibility and Information
12-1084 Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis Schreiner, Teri L., MD, MPH Nicola Haakonsen
303-724-4644
Please contact PRA for eligibility and information
12-1102 Pediatric Multiple Sclerosis and other Demyelinating Diseases Database (PeMSDD Database) Schreiner, Teri L., MD, MPH Nicola Haakonsen
303-724-4644
Please contact PRA for eligibility and information
16-1221 A Placebo-Controlled Multi-Center Phase IIa Dose Finding Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Forms of Multiple Sclerosis Vollmer, Timothy L., MD Nicola Haakonsen
303-724-4644
Eligibility and Information
Comparative Effects of Glatiramer Acetate and BG0012 on lymphocyte survival and metabolism Vollmer, Timothy L., MD
Greg Owens, PhD
Nicola Haakonsen
303-724-4644
Please contact PRA for eligibility and information